Bristol-Myers Squibb Company
$164.82B- Market cap
- $129.92B
- Debt
- +$45.11B
- Cash
- −$10.21B
Capital structure 74% equity / 26% debt · EV / Revenue 3.42x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: BMY stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs AMGN P/E.
Implied fair value · at BMY's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 74% equity / 26% debt · EV / Revenue 3.42x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$59.11
Base
$72.93
Bull
$92.88
Amgen Inc. · implied price per share
Bear
$98.66
Base
$130.87
Bull
$172.82
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
BMY vs PFE
Merck & Co., Inc.
BMY vs MRK
AbbVie Inc.
BMY vs ABBV
Eli Lilly and Company
BMY vs LLY
Gilead Sciences, Inc.
BMY vs GILD
REGENERON PHARMACEUTICALS, INC.
BMY vs REGN
BIOGEN INC.
BMY vs BIIB
VERTEX PHARMACEUTICALS INC / MA
BMY vs VRTX
Moderna, Inc.
BMY vs MRNA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BMY can restore positive net income and materially reduce Net Debt/EBITDA (from 9.7x toward AMGN-like levels) within a multi-year horizon, then consider accumulation because the stock trades at a modest P/S (2.3x) and EV/Revenue (3.2x) versus AMGN (P/S 5.5x, EV/Revenue 5.9x), which could support meaningful upside if profitability and leverage normalize.
BMY's current share price ($55.05) is far below AMGN-implied valuation ($130.78) but sits inside its historical band ($49.55 - $60.55). The discount versus a AMGN-based multiple is driven largely by BMY's negative earnings and elevated net leverage, which make some multiples (P/E) inapplicable.
Supporting Metrics